Literature DB >> 16739324

The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.

Akira Hirano1, Tadao Shimizu, Hiroshi Imamura, Osamu Watanabe, Jun Kinoshita, Toshihiro Okabe, Kiyomi Kimura, Mari Kamimura, Kaoru Domoto, Motohiko Aiba, Kenji Ogawa.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the activity and toxicity of epirubicin plus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer. PATIENTS AND METHODS: In this single-center, phase II trial, twenty-one patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (70 mg/m2) and docetaxel (60 mg/m2) on Day 1 of each cycle for up to 6 cycles.
RESULTS: Clinically complete responses (CR) were observed in 5 patients and partial responses were observed in 14 patients. The clinical response rate was 90.5% (95% confidence interval, 78.0-99.9). Eleven patients (52.4%) underwent breast conserving surgery. Pathological response evaluation revealed 2 CR (9.5%). Grade 4 neutropenia was recorded in 81.0% of the patients and febrile neutropenia occurred in 1 patient.
CONCLUSION: The combination of epirubicin plus docetaxel was an active and well-tolerated treatment for locally-advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16739324

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen.

Authors:  Iheoma Y Nwaogu; Oluwadamilola M Fayanju; Donna B Jeffe; Julie A Margenthaler
Journal:  Mol Clin Oncol       Date:  2015-06-10

2.  Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.

Authors:  Violette Renard Recinos; Kimon Bekelis; Shira G Ziegler; Ditty Vick; Samuel Hertig; Betty M Tyler; Khan W Li; Thomas Kosztowski; Federico G Legnani; Henry Brem; Alessandro Olivi
Journal:  J Neurooncol       Date:  2009-08-20       Impact factor: 4.130

3.  Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy.

Authors:  Talita Garcia do Nascimento; Marceila de Andrade; Rosemeire Aparecida de Oliveira; Ana Maria de Almeida; Thais de Oliveira Gozzo
Journal:  Rev Lat Am Enfermagem       Date:  2014 Mar-Apr

4.  Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer.

Authors:  Gharbi Olfa; Trabelsi Amel; Chafai Rim; Zayen Aymen; Ezzairi Faten; Hochlef Makrem; Ben Fatma Leila; Landolsi Amel; Khairi Hedi; Mokni Moncef; Ben Ahmed Slim
Journal:  World J Oncol       Date:  2010-08-29

5.  Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.

Authors:  Hye Sung Won; Yong Seok Kim; Jeong Soo Kim; Eun Deok Chang; Sae Jung Na; In Yong Whang; Dong Soo Lee
Journal:  Korean J Intern Med       Date:  2020-02-21       Impact factor: 2.884

6.  Do all patients with breast cancer benefit from neoadjuvant chemotherapy?

Authors:  Kyoung Eun Lee
Journal:  Korean J Intern Med       Date:  2020-10-28       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.